Business Wire

NEXTEK-LIMITED

Share
Award-winning British Recycling Project, NEXTLOOPP, Hits Bullseye in Plastics Recycling Ahead of COP26

NEXTLOOPP, the groundbreaking project by Nextek Limited, that recently won the overall award for ‘Best Sustainable Packaging Innovation’ at Packaging Europe’s Sustainability Awards - https://packagingeurope.com/sustainability-awards-2021-winners-revealed/ has revealed the results of its highly successful tracer-based sorting trials held at TOMRA (Germany) in September 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005464/en/

The trials, to specifically sort food-grade plastic packaging waste, achieved a resounding 99.9% sorting purity at maximum production speed.

This demonstrates that Nextek’s unique technology efficiently differentiates food packaging from non-food packaging to meet the standards required by the Food Standards Authorities in the UK and EU. Being able to identify and sort any number of pack variants from bleach bottles to milk bottles in any plastic type is a world-first that will transform the way we recycle the prolific volume of single-use post-consumer food packaging waste back into circular applications.

This announcement marks 12 months of NEXTLOOPP’s programme to close the loop on food-grade Polypropylene (FGPP), which is the biggest plastic fraction in the FMCG sector. In the UK alone, 210,000 tonnes of FGPP packaging is used in pots, tubs, trays and films each year, and this cutting-edge innovation creates the opportunity to recycle Polypropylene (PP) back into food packaging.

This also heralds a new era in the plastics packaging recycling industry and the validation of NEXTLOOPP’s PolyPRISMTM ‘plug-and-play’ marker system, as used on TOMRA’s sorting equipment for commercial purposes.

Sorting plastic waste into polymer types is the first of three vital steps needed to close the loop on PP and create a global low carbon economy. The next step requires splitting the plastic packaging into food and non-food fractions. The final step involves NEXTLOOPP’s patented decontamination process, PPristineTM , which unlocks the markets to food packaging. Recycling 63,000 tonnes of PP per annum would save a minimum estimated 105,600 tonnes in CO2 emissions in the UK each year.

“During recent trials held at our TOMRA Test Centre we achieved very promising results on all Polypropylene 3D samples in all test runs with state-of-the-art NIR/VIS technology. We exceeded the required 95% purity for food-grade in each test run. The next important milestones will be a field demonstration as well as demonstrating chemical compliance with food-grade regulation” said Ralph Uepping, Technical Director at TOMRA.

Professor Edward Kosior, founder of Nextek, believes the NEXTLOOPP project is the catalyst to transform current FGrPP recycling and become the next food-grade recycling success story. PET was first and now it’s the turn of PP.

About Nextek Ltd

Nextek is a global sustainability consultancy that provides strategic advice to regional and multi-national organisations and recycling companies. Launched in 2004, Nextek researches and develops innovative strategies and processes within the recycling ecosystem – from designing recycling plants to developing ground-breaking projects for governments and major organisations. Nextek launched NEXTLOOPP, a two-year 37-strong project, to close the loop on food-grade recycled Polypropylene (rPP). This project incorporates unique technological breakthroughs that include innovative sorting and cutting-edge decontamination technologies.

https://www.nextek.org/

https://www.nextloopp.com

About Tomra

TOMRA is a Norwegian multinational corporation that manufactures collection and sorting products, such as reverse vending machines for the food, recycling and mining industries. TOMRA is the market leader in its industry with over 100,000 installations in 80+ markets worldwide. Its Recycling Division has pioneered the automation of waste sorting.

https://www.tomra.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye